Choline alfoscerate
Choline alfoscerate is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| choline c 11 | New Drug Application | 2024-12-17 |
| first aid shot therapy hangover relief | OTC monograph not final | 2015-06-04 |
| first aid shot therapy pain relief | OTC monograph not final | 2015-01-21 |
| gabavale-5 | unapproved drug other | 2011-08-01 |
| gabazolamine | unapproved drug other | 2011-08-18 |
| gabazolamine-0.5 | unapproved drug other | 2011-08-01 |
| gabazolpidem-5 | unapproved drug other | 2011-08-01 |
| gabitidine | unapproved drug other | 2011-08-01 |
| gaboxetine | unapproved drug other | 2011-08-01 |
| kroger cough cold and flu | OTC monograph final | 2016-06-30 |
Show 20 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
326 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | 3 | — | 4 | 4 | 11 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | 4 | 5 | 10 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | — | 3 | 6 | 9 |
| Dyslipidemias | D050171 | HP_0003119 | — | 3 | 2 | 2 | 2 | 1 | 9 |
| Glaucoma | D005901 | EFO_0000516 | H40 | — | — | 2 | 1 | 5 | 8 |
| Fatty liver | D005234 | EFO_0003934 | — | — | — | 2 | 1 | 4 | 7 |
| Ischemia | D007511 | EFO_0000556 | — | 2 | — | 3 | 1 | 1 | 7 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | 3 | 2 | 6 |
| Cerebral infarction | D002544 | — | I63 | — | — | 3 | 1 | 1 | 5 |
| Infarction | D007238 | EFO_0009463 | — | — | — | 1 | 2 | 2 | 5 |
Show 37 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 7 | 10 | 5 | — | 29 | 46 |
| Syndrome | D013577 | — | — | 2 | 4 | 4 | — | 4 | 12 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | — | 1 | 2 | — | 7 | 10 |
| Hypertriglyceridemia | D015228 | EFO_0004211 | — | 3 | 2 | 1 | — | 1 | 7 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 1 | 1 | — | 4 | 7 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | — | 2 | — | 4 | 7 |
| Hyperparathyroidism | D006961 | EFO_0008506 | E21.3 | — | 1 | 1 | — | 4 | 6 |
| Fibrosis | D005355 | — | — | — | 1 | 1 | — | 4 | 6 |
| Prader-willi syndrome | D011218 | Orphanet_739 | Q87.11 | 1 | 2 | 4 | — | — | 6 |
| Hepatolenticular degeneration | D006527 | Orphanet_905 | E83.01 | 2 | 1 | 1 | — | 1 | 5 |
Show 30 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | — | 3 | — | — | 6 | 9 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | — | 3 | — | — | 6 | 9 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 2 | — | — | 6 | 8 |
| Fetal alcohol spectrum disorders | D063647 | — | Q86.0 | 1 | 5 | — | — | 1 | 6 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | 1 | — | — | 4 | 5 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | 3 | 4 |
| Covid-19 | D000086382 | — | — | 3 | 2 | — | — | — | 4 |
| Leukemia | D007938 | — | C95 | 1 | 2 | — | — | — | 3 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 2 | — | — | — | 2 |
| Triple negative breast neoplasms | D064726 | — | — | — | 1 | — | — | 1 | 2 |
Show 25 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 6 | — | — | — | 12 | 18 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | 2 | — | — | — | 3 | 5 |
| Recurrence | D012008 | — | — | 2 | — | — | — | 3 | 5 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | — | — | — | 3 | 4 |
| Child development | D002657 | — | — | 3 | — | — | — | 1 | 4 |
| Diet therapy | D004035 | — | — | 1 | — | — | — | 2 | 3 |
| Male infertility | D007248 | EFO_0004248 | N46 | 1 | — | — | — | — | 1 |
| Infertility | D007246 | HP_0000789 | — | 1 | — | — | — | — | 1 |
| Esophageal neoplasms | D004938 | — | C15 | 1 | — | — | — | — | 1 |
| Immunization | D007114 | — | — | 1 | — | — | — | — | 1 |
Show 9 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart disease risk factors | D000082742 | — | — | — | — | — | — | 6 | 6 |
| Depression | D003863 | — | F33.9 | — | — | — | — | 4 | 4 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | — | 4 | 4 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | — | 3 | 3 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | — | — | 3 | 3 |
| Neuralgia | D009437 | EFO_0009430 | — | — | — | — | — | 2 | 2 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | — | — | — | 2 | 2 |
| Heart failure | D006333 | HP_0001635 | I50 | — | — | — | — | 2 | 2 |
| Neuroendocrine carcinoma | D018278 | — | — | — | — | — | — | 2 | 2 |
| Thyroid diseases | D013959 | HP_0000820 | E00-E07 | — | — | — | — | 2 | 2 |
Show 87 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Choline alfoscerate |
| INN | choline alfoscerate |
| Description | Choline alfoscerate is a member of the class of phosphocholines that is the choline ester of sn-glycero-3-phosphate. It is one of the major osmolyte in the renal medullary cells. It has a role as a parasympatholytic, a neuroprotective agent, a human metabolite, a Saccharomyces cerevisiae metabolite, an Escherichia coli metabolite and a mouse metabolite. It is a member of sn-glycerol 3-phosphates and a member of phosphocholines. |
| Classification | Small molecule |
| Drug class | phosphoro-derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[N+](C)(C)CCOP(=O)([O-])OC[C@H](O)CO |
Identifiers
| PDB | — |
| CAS-ID | 28319-77-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1567463 |
| ChEBI ID | 16870 |
| PubChem CID | 657272 |
| DrugBank | DB04660 |
| UNII ID | 60M22SGW66 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 24,468 documents
View more details
Safety
Black-box Warning
Black-box warning for: Gaboxetine, Nestabs, Nestabs dha, Pre-tabs dha, Sentraflox am-10, Sentravil pm-25, Sentroxatine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
24 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use